ReviewFrontiers in immunology2025
Liquid-liquid phase separation: an emerging perspective on the tumorigenesis, progression, and treatment of tumors.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Liquid-liquid phase separation-related gene signature characterizes prognostic subtypes and therapeutic sensitivities in gastric cancer.Translational cancer research · 2026Article
- Comprehensive analysis of liquid-liquid phase separation-related genes in osteosarcoma: implications for prognosis, immune infiltration and drug sensitivity.Translational cancer research · 2026Article
- Liquid-Liquid Phase Separation in Cancer Drug Resistance: Mechanisms and Therapeutic Opportunities.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research in the field of Liquid-liquid phase separation (LLPS) breaks through the classical theory of gene mutation in the mechanism of tumorigenesis and provides a new perspective for comprehending tumors from a network regulation standpoint. Although there have been some reviews discussing the relationship between LLPS and tumors, they often focus on elaborating isolated mechanisms. In the face of complex and diverse disease characteristics, it is necessary to summarize the correlation between LLPS and tumors through a linked and holistic approach to reveal the deep-rooted relationships among tumor disease mechanisms. Therefore, we adopt a dual-dimensional analytical framework, where one dimension (the longitude) integrates cellular physiology, tumorigenesis, progression, and therapeutic responses, while the other dimension (the latitude) focuses on the pathogenic characteristics of tumors. This structural design enables comprehensive analysis of LLPS functions across both dynamic processes and pathological features. This article first outlines how LLPS regulates normal cellular physiological activities, such as gene expression, DNA damage response (DDR), and epigenetic modifications. It then summarizes how LLPS malfunction promotes tumorigenesis and progression, including the oncogenic processes of fusion oncoproteins (FOs) expression, tumor suppressor gene mutation, epigenetic modification defect, and DDR repair abnormality, as well as the tumor progression processes of proliferation and metastasis, dysregulation of autophagy, and metabolic reprogramming. Promising therapeutic strategies are then proposed. Finally, the existing research is prospected. The above insights drive the innovation of LLPS-based tumor therapeutic strategies and the development of targeted antitumor drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.